DoP is implementing PLI Scheme for Pharma with total financial outlay of Rs 15,000 crore: MoS for Chemicals and Fertilizers

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-08-03 06:00 GMT   |   Update On 2024-08-08 11:01 GMT
Advertisement

New Delhi: The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28.

This was stated by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Lok Sabha in reply to a question.

The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing, the Minister further added.

The 8 orphan drugs approved include Nitisinone indicated for treatment of Hereditary Tyrosinemia Type 1, Cannabidiol indicated for Dravet-Lennox Gastaut syndrome, Nusinersen to treat Spinal Muscular Atrophy.

The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:

S. No.

Name of the product

Usage

1

Nitisinone

Treatment of Hereditary Tyrosinemia Type 1

2

Nusinersen

Treatment of Spinal Muscular Atrophy

3

Rufinamide

Treatment of Lennox-Gastaut syndrome.

4

Sodium Phenyl Butyrate

Treatment of Urea Cycle Disorders

5

Tiopronin

Prevention of Cystine Nephrolithiasis

6

Trientine Hydrochloride

Treatment of Wilson's disease

7

Eliglustat

Treatment of Gaucher’s disease

8

Cannabidiol

Treatment of Dravet-Lennox Gastaut syndrome

Read also: JP Nadda says Govt vigilant about quality of medicines

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News